Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 101 to 150 of 298 results for breast cancer

  1. Image-guided high intensity focused ultrasound to treat breast cancer

    Register an interest in this interventional procedure   ...

    Interventional procedures guidance
    Topic selection

  2. Effectivness of 26 Gy in 5 fractions over 1 week regimen in people receiving breast construction- What is the effectiveness of radiotherapy given in 26 Gy in 5 fractions over 1 week compared with 40 Gy in 15 fractions over 3 weeks in people with early or locally advanced invasive breast cancer who are offered breast reconstruction?

    Effectivness of 26 Gy in 5 fractions over 1 week regimen in people receiving breast construction- What is the effectiveness of...

    Research recommendation
    Published
    7 August 2023

  3. Lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedema (IPG785)

    Evidence-based recommendations on lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedema in adults. This involves diverting some of the lymphatic vessels around where lymph nodes have been removed to nearby veins.

    Interventional procedures guidance
    Published
    16 April 2024
    View recommendations

    Sections for IPG785

  4. Entrectinib for treating NTRK fusion-positive solid tumours (TA644)

    Evidence-based recommendations on entrectinib (Rozlytrek) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children over 12 years.

    Technology appraisal guidance
    Published
    12 August 2020
    View recommendations

    Sections for TA644

  5. Adjuvant bisphosphonate therapy:- Which groups of people with early and locally advanced breast cancer would benefit from the use of adjuvant bisphosphonates?

    bisphosphonate therapy:- Which groups of people with early and locally advanced breast cancer would benefit from the use of adjuvant...

    Research recommendation
    Published
    11 December 2018

  6. Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]

    Awaiting development [GID-TA11411] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Spinal metastases and metastatic spinal cord compression (NG234)

    This guideline covers recognition, referral, investigation and management of spinal metastases and metastatic spinal cord compression (MSCC). It is also relevant for direct malignant infiltration of the spine and associated cord compression. It aims to improve early diagnosis and treatment to prevent neurological injury and improve prognosis.

    NICE guideline
    Published
    6 September 2023
    View recommendations

    Sections for NG234

  8. NICE recommends that a national registry is developed to collect data on the use of the RD-100i OSNA system in detecting sentinel lymph node metastases during breast cancer surgery. It also recommends that data on all patients having whole lymph node analysis by the RD-100i OSNA system should be submitted to this registry. These data should be integrated with data from other registries for breast cancer where appropriate.

    RD-100i OSNA system in detecting sentinel lymph node metastases during breast cancer surgery. It also recommends that data on all...

    Research recommendation
    Published
    9 June 2015

  9. Image-guided radiofrequency excision biopsy of breast lesions (IPG308)

    Evidence-based recommendations on image-guided radiofrequency excision biopsy of breast lesions. This involves inserting a probe that uses radiofrequency energy to cut through the breast internally, and removing the lump with a small area of surrounding tissue to test for cancer.

    Interventional procedures guidance
    Published
    22 July 2009
    View recommendations

    Sections for IPG308

  10. NICE impact prostate cancer

    Find out about the progress made by the health and care system in implementing NICE guidance on prostate cancer

  11. Prevention of chemotherapy induced nausea and vomiting in adults: netupitant/palonosetron (ESNM69)

    Summary of the evidence on netupitant/palonosetron to prevent chemotherapy induced nausea and vomiting to inform local NHS planning and decision-making

    Evidence summary
    Published
    1 March 2016

  12. Signatera for detecting molecular residual disease from solid tumour cancers (MIB307)

    NICE has developed a medtech innovation briefing (MIB) on Signatera for detecting molecular residual disease from solid tumour cancers .

    Medtech innovation briefing
    Published
    4 October 2022

  13. Combined oral contraception: nomegestrol/estradiol (Zoely) (ESNM28)

    Summary of the evidence on nomegestrol/estradiol (Zoely) for use as combined oral contraception to inform local NHS planning and decision-making

    Evidence summary
    Published
    17 December 2013

  14. Urinary tract infection (recurrent): antimicrobial prescribing (NG112)

    This guideline sets out an antimicrobial prescribing strategy for preventing recurrent urinary tract infections in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.

    Antimicrobial prescribing guideline
    Published
    31 October 2018
    View recommendations

    Sections for NG112

  15. Diagnostics Assessment Programme

    system and Metasin test) for detecting sentinel lymph node metastases in breast cancer August 2013 DG8 Review decision DG9 EGFR‑TK...

  16. Maternal and child nutrition (PH11)

    This guideline covers the nutrition of pregnant women, including women who are planning to become pregnant, mothers and other carers of children aged under 5 and their children. In particular, it aims to address disparities in the nutrition of low-income and other disadvantaged groups compared with the general population.

    Public health guideline
    Last updated
    1 November 2014
    View recommendations

    Sections for PH11

  17. Rapid genetic testing:- Research is recommended to determine the benefits and harms of creating rapid access to genetic testing for people with newly diagnosed breast cancer. This research should address the optimum model for service delivery and organisation, the clinical and cost effectiveness of such a change, uptake outcomes and patients' experience. [new 2013]

    creating rapid access to genetic testing for people with newly diagnosed breast cancer. This research should address the optimum model...

    Research recommendation
    Published
    9 June 2015

  18. Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]

    Awaiting development [GID-TA10723] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  19. Electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma (IPG446)

    Evidence-based recommendations on electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma. This involves applying short, powerful pulses of electricity to the tumour, allowing an anticancer drug to pass through into the cells.

    Interventional procedures guidance
    Published
    27 March 2013
    View recommendations

    Sections for IPG446

  20. Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer ID6433

    Awaiting development [GID-TA11489] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  21. Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer TS ID 11769

    Awaiting development [GID-TA11088] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  22. Efectiveness of 26 Gy in 5 fractions over 1 week regimen in people receiving nodal irradiation- What is the effectiveness of radiotherapy given in 26 Gy in 5 fractions over 1 week compared with 40 Gy in 15 fractions over 3 weeks in people with early or locally advanced invasive breast cancer who are also offered nodal irradiation?

    fractions over 3 weeks in people with early or locally advanced invasive breast cancer who are also offered nodal irradiation? Any...

    Research recommendation
    Published
    7 August 2023

  23. Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast cancer [ID6152]

    Awaiting development [GID-TA11089] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  24. Image-guided vacuum-assisted excision biopsy of benign breast lesions (IPG156)

    Evidence-based recommendations on image-guided vacuum-assisted excision biopsy for benign breast lesions. This involves inserting a needle with a suction device through a small opening in the breast to remove non-cancerous lumps.

    Interventional procedures guidance
    Published
    22 February 2006
    View recommendations

    Sections for IPG156

  25. What is the adherence to, and satisfaction with, different intervention formats (for example, individual, group, virtual, and face to face) to reduce arm and shoulder problems after breast cancer surgery or radiotherapy, and what is the impact of greater adherence on effectiveness for different groups, such as: women, men, trans people and non-binary people people from minority ethnic family backgrounds people with learning disabilities or cognitive impairment, or physical disabilities, or both neurodiverse people?

    virtual, and face to face) to reduce arm and shoulder problems after breast cancer surgery or radiotherapy, and what is the impact of...

    Research recommendation
    Published
    5 May 2023

  26. What is the adherence to, and satisfaction with, different intervention formats (for example, individual, group, virtual, and face to face) to reduce arm and shoulder problems after breast cancer surgery or radiotherapy, and what is the impact of greater adherence on effectiveness for different groups, such as: women, men, trans people and non-binary people people from minority ethnic family backgrounds people with learning disabilities or cognitive impairment, or physical disabilities, or both neurodiverse people?

    virtual, and face to face) to reduce arm and shoulder problems after breast cancer surgery or radiotherapy, and what is the impact of...

    Research recommendation
    Published
    7 August 2023

  27. What is the most effective and cost-effective way of delivering the intervention (for example, type of physiotherapy or exercise, mode of delivery, number of sessions) to reduce arm and shoulder problems after breast cancer surgery or radiotherapy, and what is the acceptability of the intervention for different groups, such as: women, men, trans people and non-binary people people from minority ethnic family backgrounds people with learning disabilities or cognitive impairment, or physical disabilities, or both neurodiverse people?

    delivery, number of sessions) to reduce arm and shoulder problems after breast cancer surgery or radiotherapy, and what is the...

    Research recommendation
    Published
    5 May 2023

  28. Postnatal care (NG194)

    This guideline covers the routine postnatal care that women and their babies should receive in the first 8 weeks after the birth. It includes the organisation and delivery of postnatal care, identifying and managing common and serious health problems in women and their babies, how to help parents form strong relationships with their babies, and baby feeding. The recommendations on emotional attachment and baby feeding also cover the antenatal period.

    NICE guideline
    Published
    20 April 2021
    View recommendations

    Sections for NG194

  29. Maintaining and updating our guideline portfolio

    guidelines into 'topic suites'. We've started with the following: breast cancer cardiometabolic disease prevention and treatment mental...

  30. Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID 5072]

    Awaiting development [GID-TA10960] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  31. Strategies to reduce arm and shoulder problems- What is the most effective and cost-effective way of delivering the intervention (for example, type of physiotherapy or exercise, mode of delivery, number of sessions) to reduce arm and shoulder problems after breast cancer surgery or radiotherapy, and what is the acceptability of the intervention for different groups, such as: women, men, trans people and non-binary people people from minority ethnic family backgrounds people with learning disabilities or cognitive impairment, or physical disabilities, or both neurodiverse people?

    delivery, number of sessions) to reduce arm and shoulder problems after breast cancer surgery or radiotherapy, and what is the...

    Research recommendation
    Published
    7 August 2023

  32. Care and support of people growing older with learning disabilities (NG96)

    This guideline covers care and support for adults with learning disabilities as they grow older. It covers identifying changing needs, planning for the future, and delivering services including health, social care and housing. It aims to support people to access the services they need as they get older.

    NICE guideline
    Published
    11 April 2018
    View recommendations

    Sections for NG96

  33. Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]

    In development [GID-TA11400] Expected publication date: TBC

    Technology appraisal guidance
    In development

  34. Ocrelizumab for treating relapsing–remitting multiple sclerosis (TA533)

    Evidence-based recommendations on ocrelizumab (Ocrevus) for treating relapsing–remitting multiple sclerosis in adults.

    Technology appraisal guidance
    Published
    25 July 2018
    View recommendations

    Sections for TA533

  35. Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401

    In development [GID-TA10326] Expected publication date: TBC

    Technology appraisal guidance
    In development

  36. Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive high-risk early breast cancer TS ID 11910

    Awaiting development [GID-TA11403] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  37. Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]

    In development [GID-TA11402] Expected publication date: TBC

    Technology appraisal guidance
    In development

  38. Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma (TA544)

    Evidence-based recommendations on dabrafenib (Tafinlar) with trametinib (Mekinist) for resected stage III, BRAF V600 mutation-positive melanoma in adults.

    Technology appraisal guidance
    Published
    17 October 2018
    View recommendations

    Sections for TA544

  39. Neoadjuvant endocrine therapy in postmenopausal women:- Is there a benefit for neoadjuvant endocrine therapy in postmenopausal women with early breast cancer?

    for neoadjuvant endocrine therapy in postmenopausal women with early breast cancer? Any explanatory notes(if applicable) To find out why...

    Research recommendation
    Published
    11 December 2018

  40. Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer ID 6200

    Awaiting development [GID-TA11165] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  41. Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer TS ID 12010

    Awaiting development [GID-TA11535] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  42. Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336]

    In development [GID-TA11514] Expected publication date: TBC

    Technology appraisal guidance
    In development

  43. Pembrolizumab with neoadjuvant chemotherapy and adjuvant endocrine therapy for treating ER-positive, HER2-negative early breast cancer [ID3993]

    Awaiting development [GID-TA10896] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  44. Pembrolizumab with chemotherapy for treating hormone receptor-positive HER2-negative locally recurrent inoperable or metastatic breast cancer [ID6285]

    Awaiting development [GID-TA11342] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  45. Lapatinib for breast cancer (for use in women with previously treated advanced or metastatic breast cancer) [ID20]

    Discontinued [GID-TAG387]

    Technology appraisal guidance
    Discontinued

  46. Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251]

    Awaiting development [GID-TA11273] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  47. Tucatinib with trastuzumab and pertuzumab for maintenance treatment of HER2-positive unresectable advanced breast cancer after induction chemotherapy [ID6402]

    Awaiting development [GID-TA11487] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  48. NICEimpact lung cancer

    A review of the impact our evidence-based guidance has on improvements in lung cancer.

  49. Inavolisib with palbociclib and fulvestrant for treating HR+/HER2-, PIK3CA mutated locally advanced or metastatic breast cancer TS ID 11990

    Awaiting development [GID-TA11519] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  50. Lapatinib for breast cancer (first line use in advanced or metastatic hormone-sensitive breast cancer) [ID115]

    Discontinued [GID-TAG404]

    Technology appraisal guidance
    Discontinued